Category archives for: Industry News

Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Horsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are…

Vote on Obamacare repeal bill delayed after McCain surgery

Sen. John McCain’s absence from the Senate as he recovers from surgery for a blood clot has led the GOP leadership to postpone consideration of healthcare legislation that is already on the brink.

Health systems see returns on risk-based reimbursement

Despite a broad push to provide healthcare that emphasizes value over volume, health systems still largely rely on a fee-for-service model as they gradually take on more financial risk through new payment methods.

Analysts predict drop in provider net revenue under BCRA

Medicaid cuts, coupled with other policy changes proposed in the latest version of the Better Care Reconciliation Act, could dramatically increase the number of uninsured and reverse gains made in preventive and primary care.

Q&A with Hinton: 'Payers are not enemies'

James Hinton, having just stepped down as president at Baylor Scott & White Health recently spoke with Modern Healthcare Editor Aurora Aguilar.

CMS looks to drop payment for off-campus services by half

The CMS wants to further reduce the rate for services offered at off campus hospital facilities.

What does $15 billion in overdue bills mean for doctors and hospitals in Illinois?

Illinois may finally have a budget, but it could take months, even years, for the state to pay down its $15 billion in overdue bills.

House passes bipartisan FDA user fee bill

The House of Representatives passed bipartisan legislation Wednesday that reauthorizes the FDA’s ability to collect user fees from drug and device makers, as policymakers look to avoid thousands of layoffs if the current agreement expires.

FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

THOUSAND OAKS, Calif., July 11, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include…

Staffing startup Nomad Health opens platform to nurses

There will be an estimated shortage of 1.2 million nurses in the U.S. by 2022. But Nomad Health’s CEO thinks his platform can help solve that problem.

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us